Clinical Trial Update: Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer [NA]

View source ↗

Summary

A clinical trial is evaluating whether sentinel lymph node biopsy can be omitted after neoadjuvant therapy in patients with triple-negative and HER2-positive br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer | NA | Status: ACTIVE_NOT_RECRUITING